Man­u­fac­tur­ing ex­perts at Hangzhou Just Bio­ther­a­peu­tics bank $35M for stealthy R&D in Chi­na and the US

Hill­house Cap­i­tal has joined sev­er­al promi­nent in­vest­ment firms in back­ing an an­ti­body and re­com­bi­nant pro­tein com­pa­ny’s en­try to the clin­ic with $35 mil­lion.

Be­tween sites in Hangzhou and Boston, Hangzhou Just Bio­ther­a­peu­tics will ramp up R&D with the new round of fund­ing, which they are call­ing a Se­ries B+. Temasek, Lil­ly Asia Ven­tures, Arch Ven­ture Part­ners, Taikang and BOC­GI Zhe­shang Cap­i­tal are among the ex­ist­ing in­vestors that al­so chipped in, col­lec­tive­ly wa­ger­ing $120 mil­lion on HJB’s bio­man­u­fac­tur­ing and process de­vel­op­ment plat­form to date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER